Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor Ad Defends Safety, Re-Asserts Superiority Claims

Executive Summary

AstraZeneca's full-page ads responding to questions about the safety of Crestor (rosuvastatin) repeat the company's claim that the drug is more effective at lowering cholesterol than other statins

You may also be interested in...



To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go

FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor

To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go

FDA says AstraZeneca's Crestor is as safe as, if not safer than, other statins for a given LDL-lowering efficacy, but its ad campaign cannot claim superiority to Pfizer's Lipitor

Crestor Muscle Risk No Greater Than Other Statins, FDA Says; Death Reported

FDA's current view is that there is no greater risk for muscle injury with AstraZeneca's cholesterol lowering drug Crestor than with other statins, the agency said

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel